Highlights 89bio, Inc.

Equities

ETNB

US2825591033

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-10 EDT			5-day change	1st Jan Change
8.71 ^USD	-4.39%		-5.53%	-22.02%

05-10	HC Wainwright Adjusts 89bio's Price Target to $29 From $31, Maintains Buy Rating	MT
05-09	89bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

89bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
89bio's Liver Disease Drug Candidate Pegozafermin Gets EMA Priority Medicines Status	03-27	MT
89bio, Inc. Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis and Compensated Cirrhosis	03-27	CI
89Bio, Inc. Announces Initiation of Its Phase 3 Enlighten Program Evaluating the Efficacy and Safety of Pegozafermin in Patients with Metabolic Dysfunction-Associated Steatohepatitis, Formerly Known as Nonalcoholic Steatohepatitis	03-12	CI
89bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-29	CI
89bio, Inc. Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis	12-04	CI
89bio, Inc. Announces New Positive Long-Term Data from the ENLIVEN Phase 2B Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis	11-27	CI
89Bio Announces Additional Data from the Enliven Phase 2B Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis	11-12	CI
89bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
89bio Says US FDA Grants Breakthrough Therapy Label for Pegozafermin in Nonalcoholic Steatohepatitis	23-09-21	MT
89bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
89bio, Inc. Announces Data from the Phase 2B Enliven Trial Evaluating Treatment with Pegozafermin in Patients with Nonalcoholic Steatohepatitis	23-06-24	CI
89bio, Inc. Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia	23-05-23	CI
89bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
89bio, Inc. Announces Positive Topline Data from the Phase 2b ENLIVEN Trial Evaluating Treatment with Pegozafermin in Patients with Nonalcoholic Steatohepatitis	23-03-22	CI
89bio's Q4 Net Loss Narrows	23-03-10	MT
89bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-10	CI
89bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-10	CI
89bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-10	CI
89bio, Inc. Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients	23-03-04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights 89bio, Inc.

Equities

ETNB

US2825591033

Highlights

Filters